APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
89 Views
Otsuka Holdings (4578 JP): Strong 1H Result; FY Guidance Revision; Approaching Next Level Growth
Otsuka reported 1H26 result, with key parameters being ahead of guidance. The company raised 2026 revenue guidance by 8% and business profit...
100 Views
APAC Healthcare Weekly (Oct 4) – Hengrui, Hansoh, Chugai Pharma, Daiichi Sankyo, Otsuka, Sun Pharma
Hengrui stuck $2.6B outlicensing deal with Novo. EC revoked EU marketing authorization of Hansoh’s aumolertinib. Otsuka initiates NDA submission to...
97 Views
Primer: Otsuka Holdings (4578 JT) - Aug 2026
Otsuka's unique business model, combining a high-margin specialty Pharmaceutical business with a stable, cash-generative Nutraceuticals segment,...
100 Views
Primer: Otsuka Holdings (4578 JP) - Aug 2026
Otsuka operates a unique dual-engine business model, combining a high-margin, R&D-intensive Pharmaceutical business with a stable,...
99 Views